Inclusion Criteria:

- Signed written informed consent;

- Males or females between 18 and 70 years of age;

- Surgically resected squamous cell carcinomas of the hypopharynx, oropharynx, larynx
and oral cavity with high risk of locoregional recurrence not more than 6-9 weeks
(maximum) ago;

- To be categorized as high risk patients have to fulfil at least one of the following
criteria:

- R0 - resection <5 mm margin

- R1 - resection

- Extracapsular nodal extension;

- no previous chemotherapy, radiotherapy;

- Performance status ECOG: 0 - 1;

- Contraception in male and female patients if of childbearing potential, willingness
to use effective contraceptive method for the study duration and 2 months
post-dosing;

- Adequate renal, liver and hematological functions (within maximum 9 weeks until
surgery):

- Adequate bone marrow function: neutrophils > 1.5 x 10^9/L, platelets > 100 x
10^9/L, hemoglobin > 10.0 g/dL

- Adequate liver function: Bilirubin < 2.0 mg/dL, AST, ALT, AP, γ-GT < 3 x ULN

- Adequate renal function: creatinine clearance > =60 ml/min

- No distant metastases;

Exclusion Criteria:

- Nasopharyngeal carcinoma;

- R2 resection;

- Invalid informed consent;

- Performance Status > 1;

- Previous chemotherapy or radiotherapy for carcinoma of the head and neck;

- Prior exposure to EGFR pathway targeting therapy;

- Other serious illness or medical conditions:

- Unstable cardiac disease despite treatment, congestive heart failure NYHA grade
3 and 4;

- Clinically significantly abnormal electrocardiogram (ECG) or left ventricular
ejection fraction (LVEF) below the institutional range of the normal

- Significant neurologic or psychiatric disorders including dementia or seizures;

- Active uncontrolled infection;

- Active disseminated intravascular coagulation;

- Other serious underlying medical conditions which could impair the ability of
the patient to participate in the study;

- Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria
(NCI-CTC v3.0) grade 2 or ototoxicity grade 2, except if due to trauma or mechanical
impairment due to tumor mass;

- Having participated in another therapeutic clinical trial or any investigational
agent in the preceding 30 days;

- Known allergic/hypersensitivity reaction to any of the components of the treatment;

- Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding;

- Known drug abuse;

- Other previous malignancy within 5 years, with exception of a history of a previous
basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;

- Legal incapacity or limited legal capacity;

- Sensitivity and incompatibility against 5-Fluorouracil

- Sensitivity and incompatibility against platinum-compounds

- Known incompatibilities >grade 3 towards cetuximab

- expected incompliance of patient (e.g. in case of severe alcohol addiction)

- Dental evaluation: Pre treatment dental care before start of radiochemotherapy
(approximately 8 to 10 days lapse-time is needed for complete recovery before
initiation of radiation therapy).